1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Drugs In Development, 2022, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 1, 7 and 1 respectively.
Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Prosthetic Joint infections - Overview
- Prosthetic Joint infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Prosthetic Joint infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Prosthetic Joint infections - Companies Involved in Therapeutics Development
- Adaptive Phage Therapeutics Inc
- Arietis Corp
- Armata Pharmaceuticals Inc
- ContraFect Corp
- Integrated BioTherapeutics Inc
- Lumobiotics GmbH
- Osteal Therapeutics Inc
- Peptilogics Inc
- Pherecydes Pharma SA
- Qentoros Inc
- Sonoran Biosciences Inc
- TenNor Therapeutics Ltd
- Prosthetic Joint infections - Drug Profiles
- Product Description
- Mechanism Of Action
- A-103 - Drug Profile
- Product Description
- Mechanism Of Action
- APSA-02 - Drug Profile
- Product Description
- Mechanism Of Action
- BIO-PLY - Drug Profile
- Product Description
- Mechanism Of Action
- CF-296 - Drug Profile
- Product Description
- Mechanism Of Action
- exebacase - Drug Profile
- Product Description
- Mechanism Of Action
- PLG-0206 - Drug Profile
- Product Description
- Mechanism Of Action
- PP-2351 - Drug Profile
- Product Description
- Mechanism Of Action
- Prosthetic Joint Infection (PJI) - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Activate CIPP for Prosthetic Joint Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Oncology and Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- TNP-2092 - Drug Profile
- Product Description
- Mechanism Of Action
- TPH-101 - Drug Profile
- Product Description
- Mechanism Of Action
- Prosthetic Joint infections - Dormant Projects
- Prosthetic Joint infections - Discontinued Products
- Prosthetic Joint infections - Product Development Milestones
- Featured News & Press Releases
- Nov 29, 2022: Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by staphylococcus aureus
- Nov 28, 2022: ContraFect announces ANSM approval of clinical trial application for exebacase in prosthetic joint infections
- Oct 20, 2022: Peptilogics to present data at IDWeek 2022 on PLG0206, an engineered antimicrobial peptide targeting bacteria causing periprosthetic joint infection
- Oct 07, 2022: Peptilogics doses first subject in periprosthetic joint infection trial
- Sep 12, 2022: ContraFect announces presentation of new clinical data from a study using exebacase in the LysinDAIR procedure on patients with chronic knee prosthetic joint infection
- Aug 06, 2022: Peptilogics to participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
- Aug 01, 2022: Armata Pharmaceuticals announces clearance of IND for prosthetic joint infections
- Jul 19, 2022: Peptilogics receives FDA fast track designation for PLG0206, an investigational peptide therapeutic in development for the treatment of periprosthetic joint infection
- Apr 19, 2022: Peptilogics to present data highlighting designed antimicrobial peptide for the treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
- Mar 22, 2022: Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting highlight peptide therapeutic PLG0206 for the treatment of periprosthetic joint infection (PJI)
- Jan 10, 2022: Peptilogics announces FDA clearance of investigational new drug application to initiate clinical trial of PLG0206 in periprosthetic joint infection
- Dec 01, 2021: Peptilogics announces two peer-reviewed publications on designed peptide therapeutic PLG0206 for periprosthetic joint infection
- Sep 29, 2021: Peptilogics presents positive first-in-human phase 1 data for its lead engineered antibacterial peptide, PLG0206, at IDWeek 2021
- Sep 22, 2021: Peptilogics to present first-in-human phase 1 clinical data of PLG0206 at IDWeek 2021
- May 26, 2021: ContraFect announces multiple publications on exebacase, including first manuscript on local administration of lysin for potential treatment of prosthetic joint infections
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Prosthetic Joint infections, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Prosthetic Joint infections - Pipeline by Adaptive Phage Therapeutics Inc, 2022
- Prosthetic Joint infections - Pipeline by Arietis Corp, 2022
- Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, 2022
- Prosthetic Joint infections - Pipeline by ContraFect Corp, 2022
- Prosthetic Joint infections - Pipeline by Integrated BioTherapeutics Inc, 2022
- Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, 2022
- Prosthetic Joint infections - Pipeline by Osteal Therapeutics Inc, 2022
- Prosthetic Joint infections - Pipeline by Peptilogics Inc, 2022
- Prosthetic Joint infections - Pipeline by Pherecydes Pharma SA, 2022
- Prosthetic Joint infections - Pipeline by Qentoros Inc, 2022
- Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, 2022
- Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, 2022
- Prosthetic Joint infections - Dormant Projects, 2022
- Prosthetic Joint infections - Discontinued Products, 2022
- Number of Products under Development for Prosthetic Joint infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptive Phage Therapeutics Inc
- Arietis Corp
- Armata Pharmaceuticals Inc
- ContraFect Corp
- Integrated BioTherapeutics Inc
- Lumobiotics GmbH
- Osteal Therapeutics Inc
- Peptilogics Inc
- Pherecydes Pharma SA
- Qentoros Inc
- Sonoran Biosciences Inc
- TenNor Therapeutics Ltd
